Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

61.40 -0.45 (-0.73%)
Official Closing Price Updated: 4:10 PM EDT, Sep 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,907,466
Open 62.30
Bid (Size) 61.78 (2)
Ask (Size) 61.81 (12)
Prev. Close 61.85
Today's Range 60.72 - 62.32
52wk Range 45.05 - 135.20
Shares Outstanding N/A
Dividend Yield 3.58%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Could This New Drug Be The Safer Way To Fight Obesity?
Skye Bioscience reported favorable Phase 1b nimacimab results, with analysts citing strong potential in obesity alongside GLP-1 therapies. 
Via Benzinga

Performance

YTD
-29.8%
-29.8%
1 Month
+12.1%
+12.1%
3 Month
-16.8%
-16.8%
6 Month
-22.1%
-22.1%
1 Year
-53.5%
-53.5%

More News

Read More
Eli Lilly's Dual Triumph: Mounjaro Expands Reach, Orforglipron Set to Revolutionize Oral Diabetes and Weight Loss Market
Via MarketMinute
Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production
Via MarketMinute
Topics Artificial Intelligence Economy Government
Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle
Via MarketMinute
Oscar Health Set For HIMS-Style Moonshot? Shorts Could Burn As ACA Buzz Builds
Via Benzinga
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit - NVO
Via NewMediaWire
Topics Fraud Lawsuit
The Weight-Loss Craze Boosted The $186 Billion Telehealth Industry. What It Means For Investors.
Via Investor's Business Daily
Why Shares in Novo Nordisk Soared This Week
Via The Motley Fool
Why Novo Nordisk Stock Popped Again Today
Via The Motley Fool
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
Via Benzinga
Here's Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy Today
Via The Motley Fool
Topics Government
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
Via Benzinga
Topics ETFs
Novo Nordisk Poised For UNH-Style Comeback: New Data & AI Boost Signal Reversal
Via Benzinga
Topics Artificial Intelligence
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Via TheNewswire.com
Topics Fraud Lawsuit
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Via NewMediaWire
Topics Fraud Lawsuit
Novo Nordisk Pops 8% On 'Significant' Weight Loss For Oral Wegovy
Via Investor's Business Daily
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study
Via Benzinga
Why Is Everyone Talking About Novo Nordisk Stock?
Via The Motley Fool
'Offices Need To Start Feeling A Little Bit More Like Hotels,' Behind One CBRE Exec's Approach To The Future Of In-Person Work
Via Benzinga

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 61.40
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 09/19/25 04:10 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.